Challenges in managing anticoagulant therapy in patients with heart valve prostheses

References

• Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation89, 635–641 (1994).
   PubMed Web of Science ®Google Scholar
• Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N. Engl. J. Med.333, 11–17 (1995).
   PubMed Web of Science ®Google Scholar
• Ruel M, Masters RG, Rubens FD et al. Late incidence and determinants of stroke after aortical and mitral valve replacement. Ann. Thorac. Surg.78, 77–83 (2004).
   PubMed Web of Science ®Google Scholar
• ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on practice guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation114, 450–527 (2006).
   Google Scholar
• Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br. J. Haematol.132, 277–285 (2006).
   PubMed Web of Science ®Google Scholar
• Butchart EG, Gohlke-Barwolf C, Antunes MJ et al. Recommendations for the management of patients after heart valve surgery. Working groups on valvular heart disease, thrombosis, and cardiac rehabilitation and exercise physiology, European Society of Cardiology. Eur. Heart J.26, 2463–2471 (2005).
   PubMed Web of Science ®Google Scholar
• Salem DN, Stein PD, Al-Ahmad A et al. Antithrombotic therapy in valvular heart disease-native and prosthetic. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest126, 457S–482S (2004).
   PubMed Web of Science ®Google Scholar
• Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N. Engl. J. Med.322, 428–432 (1990).
   PubMed Web of Science ®Google Scholar
• Acar J, Iung B, Boissel JP et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation94, 2107–2112 (1996).
   PubMed Web of Science ®Google Scholar
• Vink R, Kraaijenhagen RA, Hutten BA et al. The optimal intensity of vitamin K antagonists in patients with mechanical heart valves; a meta-analysis. J. Am. Coll. Cardiol.42, 2042–2048 (2003).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Gent M, Laupacis A et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N. Engl. J. Med.329, 524–529 (1993).
   PubMed Web of Science ®Google Scholar
• Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J. Thorac. Cardiovasc. Surg.113, 910–916 (1997).
   PubMed Web of Science ®Google Scholar
• Heras M, Chesebro JH, Fuster V et al. High risk of thromboembolism early after bioprosthetic cardiac valve replacement. J. Am. Coll. Cardiol.25, 1111–1119 (1995).
   PubMed Web of Science ®Google Scholar
• Sundt TM, Zehr KJ, Dearani JA et al. Is early anticoagulation with warfarin necessary after biological aortic valve replacement? J. Thorac. Cardiovasc. Surg.129, 1024–1031 (2005).
   PubMed Web of Science ®Google Scholar
• Gherli T, Colli A, Fragnito C et al. Comparing warfarin with aspirin after biological aortic valve replacement. Circulation110, 496–500 (2004).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet1, 1242–1245 (1988).
   PubMed Web of Science ®Google Scholar
• Cohn LH, Collins JJ Jr, Rizzo RJ, Couper GS, Aranki SF. Twenty-year follow-up of the Hancock modified orifice porcine aortic valve. Ann. Thorac. Surg.66, S30–S34 (1998).
   Google Scholar
• Logeais Y, Langanay T, Corbineau H, Roussin R, Rioux C, Leguerrier A. Aortic valve replacement in the elderly: bioprosthesis or mechanical valve? Ann. Thorac. Surg.66, S77–S81 (1998).
   PubMed Web of Science ®Google Scholar
• Goldsmith I, Lip GY, Mukundan S, Rosin MD. Experience with low-dose aspirin as thromboprophylaxis for the Tissuemed porcine aortic bioprosthesis: a survey of five years’ experience. J. Heart Valve Dis.7, 574–579 (1998).
   PubMed Web of Science ®Google Scholar
• Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest119, 194S–206S (2001).
   PubMed Web of Science ®Google Scholar
• Schaefer C, Hanneman D, Meister R et al. Vitamin K antagonists and pregnancy outcome. A multicenter prospective study. Thromb. Haemost.95, 922–923 (2006).
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve prostheses. Br. Heart J.71, 196–201 (1994).
   PubMedGoogle Scholar
• Wong V, Cheng CH, Chan KC. Fetal and neonatal outcome of exposure to anticoagulants during pregnancy. Am. J. Med. Genet.45, 17–21 (1993).
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Hashiguchi K, Akizawa Y, Saito R, Ohta H. A case of fetal subdural hematoma at 31 weeks of gestation in a woman on warfarin therapy after Cabrol’s operation. Fetal Diagn. Ther.18, 252–254 (2003).
   PubMed Web of Science ®Google Scholar
• Lee HC, Cho SY, Lee HJ, Kim CJ, Park JS, Chi JG. Warfarin assocoated fetal intracranial hemorrhage: a case report. J. Kor. Med. Sci.18, 764–767 (2003).
   PubMed Web of Science ®Google Scholar
• Salazar E, Izaguirre R, Verdejo J Mutchinick O. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J. Am. Coll. Cardiol.27, 1698–1703 (1996).
   PubMed Web of Science ®Google Scholar
• Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest126, 627S–644S (2004).
   PubMed Web of Science ®Google Scholar
• Kovacs MJ, Kearon C, Rodger M et al. Single-arm study of bridging therapy with low molecular weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation110, 1658–1663 (2004).
   PubMed Web of Science ®Google Scholar
• James AH, Brancazio LR, Gehrig TR, Wang A, Ortel TL. Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves. J. Matern. Fetal Neonatal Med.19, 543–549 (2006).
   PubMed Web of Science ®Google Scholar
• Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N. Engl. J. Med.336, 1506–1511 (1997).
   PubMed Web of Science ®Google Scholar
• Heit JA. Perioperative management of the chronically anticoagulated patient. J. Thromb. Thrombolysis12, 81–87 (2001).
   PubMed Web of Science ®Google Scholar
• Seshadri MN, Goldhaber SZ, Elkayam U. The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical heart valves: an evidence-based comparative review focusing on anticoagulant options in pregnant and nonpregnant patients. Am. Heart J.150, 27–34 (2005).
   PubMed Web of Science ®Google Scholar
• Shapira Y, Vaturi M, Sagie A. Anticoagulant management of patients with mechanical heart prosthetic valves undergoing non-cardiac surgery: indications and unresolved issues. J. Heart Valve Dis.10, 380–387 (2001).
   PubMed Web of Science ®Google Scholar
• Palareti G, Legnani C, Guazzaloca G. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants – a prospective study. Thromb. Haemost.72, 222–226 (1994).
   PubMed Web of Science ®Google Scholar
• Genewein U, Haerberk A, Straub PW. Rebound after cessation of oral anticoagulant therapy. The biochemical evidence. Br. J. Haemat.92, 279–285 (1996).
   Google Scholar
• Vink R, van Dongen CJJ, Jacobs R et al. Thromboembolic and bleeding complications during non-cardiac surgery in patients with mechanical heart valves. J. Thromb. Haemost.3(Suppl. 1) (2005) (Abstract P0421).
   Google Scholar
• Douketis JD, Johnson JA, Turpie AG. Low molecular weight heparin as bridging anticoagulation during interruption of warfarin. Arch. Intern. Med.164, 1319–1326 (2004).
   PubMedGoogle Scholar
• Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann. Intern. Med.144, 673–684. (2006).
   PubMed Web of Science ®Google Scholar
• Kuvin JT, Harati NA, Pandian NG, Bojar RM, Khabbaz KR. Postopeative cardiac tamponade in the modern surgical era. Ann. Thorac. Surg.74, 1148–1153 (2002).
   PubMed Web of Science ®Google Scholar
• Kulik A, Rubens FD, Wells PS et al. Early post-operative anticoagulation after mechanical heart valve replacement: a systematic review. Ann. Thorac. Surg.81, 770–781 (2006).
   PubMed Web of Science ®Google Scholar
• Dorffler-Mely J, de Jonge E, de Pont AC et al. Bioavailability of subcutaneous low molecular weight heparin to patients on vasopressors. Lancet359, 849–850 (2002).
   PubMed Web of Science ®Google Scholar
• Montelascot GM, Polle V, Collet JP et al. Low molecular weight heparin after mechanical heart valve replacement. Circulation101, 1083–1086 (2000).
   PubMed Web of Science ®Google Scholar
• Meurin P, Tabet JY, Weber H, Renaud N, Ben Driss A. Low molecular weight heparin as a bridging anticoagulant early after mechanical heart valve replacement. Circulation113, 564–569 (2006).
   PubMed Web of Science ®Google Scholar
• Close V, Purohit M, Tanos M, Hunter S. Should patients post-cardiac surgery be given low molecular weight heparin for deep vein thrombosis prophylaxis? Int. Cardiovasc. Thorac. Surg.5, 624–629 (2006).
   PubMedGoogle Scholar